-
Award for Hereford Singing Group
Q2 (Quivers and Quavers), Hereford’s innovative voice therapy singing group, has been awarded a special Judges Award at the West Midlands National Health and Social Care Awards.
-
Alzheimer’s and Parkinson’s Medicines Guidelines
The European Medicines Agency (EMEA) has released two guidelines for companies developing medicines for the treatment of Alzheimer’s and other dementias, and for Parkinson’s, in the light of recent scientific progress in the understanding of these conditions.
-
Deep Brain Stimulation Halts Cell Loss
Preliminary research by scientists at the Neuroscience Institute at the University of Cincinnati (UC) and University Hospital, in the US, has suggested that deep brain stimulation (DBS) halts the progression of dopamine cell loss in animal models.
-
Pain and Involuntary Muscle Contractions
A recent study by Italian researchers, based at the University of Bari, published in the September issue of Archives of Neurology, has suggested that pain is associated with Parkinson’s.
-
Mervyn Peake Awards Celebrate Creativity
This year’s Mervyn Peake Awards, hosted by the Parkinson’s Disease Society of the United Kingdom in July, honoured the creative talents of people with Parkinson’s in art, poetry and photography.
-
A Good Night’s Sleep
The Parkinson’s Disease Society of the United Kingdom (PDS) has been awarded over £400,000 of lottery funding for research into sleep disorders and Parkinson’s.
-
Michael J Fox Foundation Awards $2 Million Grant
Five research teams from the US, Canada and the Netherlands have been awarded funding totalling $2 million by the Michael J Fox Foundation for preclinical and clinical research projects in Parkinson’s diseaserelated cognitive deficits and mood disorders.
-
Vitamin D Deficiency Research
Research published in the October issue of Archives of Neurology suggests that people with Parkinson’s are more likely to be vitamin D deficient than adults without the disorder of the same age or people with Alzheimer’s disease.
-
Gene Therapy Research
Amsterdam Molecular Therapeutics (AMT), a leading human gene therapy company, has obtained a licence from Amgen to use their glial-cell derived neurotrophic factor (GDNF) for the development of a gene therapy treatment for Parkinson’s.
-
Google Co-founder Admits Parkinson’s Fear
Sergey Brin, co-founder of the popular Internet search engine Google, has recently revealed on a personal internet blog that he has a genetic mutation that increases his chances of getting Parkinson’s later in life. His mother Eugenia (who also has the mutation) and her aunt developed the condition.
-
Pfizer to Stop Manufacturing High-dose Cabaser
Pfizer is to stop manufacturing and marketing the highest dose of its anti-Parkinson medication, Cabaser (generic name cabergoline), after a European safety review.
-
Green-glowing Protein
Dwain Morris-Irvin of Cedars- Sinai Medical Center (US) and Lund University in Sweden says a green-glowing protein and other new approaches are being used to help find a cure for Parkinson's disease and other neurodegenerative brain disorders.
-
Dopamine Agonists
German neurologist Georg Ebersbach discusses the current use of dopamine agonist medication.
-
Banking for Future Discoveries
PD GEN, the PD MED/PD SURG Parkinson’s Disease DNA Bank, is an invaluable resource designed to advance genetic research, as Karen Morrison explains.
-
Pursuing Best Practice in Multidisciplinary Care
The Dutch ParC Center team discuss the development of their new clinical practice guidelines
-
Caring for the Carer
Bridget McCall provides a checklist for carers to help them cope with their demanding role
-
Tricks and Tips
Mariella Graziano explains how patients’ self-help strategies have a lot to teach healthcare professionals.
